We are live on
!
Find out more
JHC
Jones Hill Capital Portfolio holdings
AUM
$470M
This Fund
S&P 500
This Quarter
Est. Return
+9.39%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$470M
AUM Growth
+$3.89M
(+0.83%)
Cap. Flow
-$35.1M
Cap. Flow
% of AUM
-7.45%
Top 10 Holdings %
Top 10 Hldgs %
68.84%
Holding
41
New
15
Increased
5
Reduced
9
Closed
12
Avg Time Held
0.5
quarters
Top 10 Avg Time Held
0.3
quarters
Top 20 Avg Time Held
0.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$45.2M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$26.9M |
| 3 |
Arcutis Biotherapeutics
ARQT
|
+$25.4M |
| 4 |
Relmada Therapeutics
RLMD
|
+$23.1M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$43.2M |
| 2 |
Vaxcyte
PCVX
|
+$37.5M |
| 3 |
TERN
Terns Pharmaceuticals
TERN
|
+$27.5M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$24.4M |
| 5 |
Enliven Therapeutics
ELVN
|
+$23.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Enliven Therapeutics
ELVN
$2.98B
| $2.53M | 0.54% |
49,850
-543,190
| -92% | -$23.1M |
2026 Q1
1 quarter
|
|
27
Structure Therapeutics
GPCR
$1.83B
| $2.18M | 0.46% |
40,567
-60,026
| -60% | -$2.66M |
2026 Q1
1 quarter
|
|
28
Phathom Pharmaceuticals
PHAT
$577M
| $1.75M | 0.37% |
+161,486
| New | +$1.84M |
2026 Q2
0 quarters
|
|
29
Achieve Life Sciences
ACHV
$741M
| $175K | 0.04% |
+26,760
| New | +$128K |
2026 Q2
0 quarters
|
|
30
argenx
ARGX
$51.5B
| – | – |
-25,995
| Closed | -$19M | – |
|
31
Fulcrum Therapeutics
FULC
$286M
| – | – |
-1,771,926
| Closed | -$13.6M | – |
|
32
Nuvation Bio
NUVB
$1.74B
| – | – |
-2,383,031
| Closed | -$10.2M | – |
|
|
33
Vaxcyte
PCVX
$9.68B
| – | – |
-644,831
| Closed | -$37.5M | – |
|
|
34
Ultragenyx Pharmaceutical
RARE
$1.51B
| – | – |
-1,165,557
| Closed | -$24.4M | – |
|
|
SLN
35
Silence Therapeutics
SLN
$592M
| – | – |
-301,604
| Closed | -$1.59M | – |
|
|
TERN
36
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-521,237
| Closed | -$27.5M | – |
|
37
Entrada Therapeutics
TRDA
$215M
| – | – |
-374,010
| Closed | -$4.72M | – |
|
38
ArriVent BioPharma
AVBP
$824M
| – | – |
-45,809
| Closed | -$1.06M | – |
|
|
CTNM
39
Contineum Therapeutics
CTNM
$496M
| – | – |
-513,053
| Closed | -$6.7M | – |
|
|
ORKA
40
Oruka Therapeutics
ORKA
$5.12B
| – | – |
-140,843
| Closed | -$6.91M | – |
|
|
MANE
41
Veradermics Inc
MANE
$5.29B
| – | – |
-100,843
| Closed | -$6.37M | – |
|
Similar funds
AIM
BFA
ACM
HNWAG
DBRC
DWML
CFLC
PWM
Jones Hill Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Jones Hill Capital held 41 positions worth $470M, up 0.83% from $466M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Jones Hill Capital withdrew a net $35.1M in Q2 2026, closing 12 positions and reducing 9 holdings. Its most notable exit was Vaxcyte, an estimated $37.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Jones Hill Capital opened a new position in Gilead Sciences worth $43.3M.
- Jones Hill Capital's largest Q2 2026 buy was Gilead Sciences: 343,043 shares worth $43.3M.
- Jones Hill Capital added most to Relmada Therapeutics in Q2 2026, an estimated $23.1M increase.
- Jones Hill Capital's biggest Q2 2026 reduction was Vertex Pharmaceuticals, cutting an estimated $43.2M.
- Jones Hill Capital fully exited Vaxcyte in Q2 2026, selling an estimated $37.5M.
- Jones Hill Capital's ten largest holdings make up 69% of its $470M portfolio in Q2 2026.
- Jones Hill Capital opened 15 new positions and closed 12 in Q2 2026.
- Jones Hill Capital's portfolio value rose 0.83% quarter-over-quarter to $470M.
Based on Jones Hill Capital's 13F filing for Q2 2026, filed 13 Aug 2026.